Exploring Empathy and Compassion Using Digital Narratives

July 25, 2024 updated by: McGill University

Learning to Care: Exploring Empathy and Compassion Using Digital Narratives

Stories of suffering and struggle are shared continuously through digital formats such as internet videos, news stories, social marketing, and fundraising campaigns. Digital stories are often created and shared to generate awareness about a problem, impart knowledge on contemporary issues, or promote compassion. The practice of sharing critical life events and insights provided by these experiences are valuable for tellers and the listeners alike for catharsis, healing, reconciliation, and connectiveness. Portrayals of mental suffering are a matter of cultural and social interest as new media products become available to the public. Studies published since the 1990s overwhelmingly conclude that formal media depictions are biased, promoting the stereotype that people who suffer emotionally are mentally ill, dangerous, violent, or insane. Various agencies, organizations, and corporations are actively working to provide alternative stories/narratives to mainstream media by means of video testimonials in social marketing and fundraising campaigns and, ultimately, by taking advantage of the Internet. The impact of this work is under-researched. However, preliminary evaluations of social marketing campaigns report mixed results and raise questions about their effectiveness. As well, the first-person narrative prepared digitally and shared online is also providing alternative narratives to mainstream media stories. People are increasingly using digital videos to share their stories, viewing this as an opportunity to understand their emotions and thoughts, come to terms with disgrace around sensitive, personal issues and marginalization while providing hope and encouragement to others. This proposed study focuses on the process of creating digital narratives/stories, especially stories of mental and emotional suffering, and their impact in terms of inciting empathy, compassion, and good citizenship among viewers.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Digital stories -- first person, self-made 2-3-minute videos -- aim to generate awareness about problems, impart knowledge, or promote compassion. Sharing critical life events and related insights are invaluable for tellers and listeners alike, supporting catharsis, healing, reconciliation, and connectiveness. Digital stories are created and shared among organizations or citizens ( "ordinary" people without a background in filmmaking) to promote awareness of particular problems. They impact peoples' knowledge of contemporary issues, shaping attitudes by stimulating empathy, compassion, and active citizenship.

The proposed study explores digital stories/narratives, particularly those focused on mental health recovery, and how stories elicit empathy and compassion by addressing three main questions: (1) How is mental and emotional suffering depicted in video testimonies presented by social marketing/fundraising campaigns, versus the stories of ordinary people told through digital videos? (2) What impact does digital storytelling have for the creators, as ordinary people willing to revisit difficult life moments and transform them into digital videos? (3) What is the impact of video depictions on viewers in terms of empathy and compassion?

This mixed-method study has 3 phases: In Phase 1 (Preparation), a search will be conducted to identify activities related to Canadian social marketing and fundraising campaigns. Digital storytelling workshops will be held simultaneously, and in-depth interviews conducted before and after each workshop. Social service and community organizations located in Montreal, Canada, will be contacted to promote the digital storytelling workshops, to be implemented in the community and on university campuses. In Phase 2, a pilot randomized controlled trial (RCT) will be undertaken and more in-depth interviews conducted. Phase 3 will consist of knowledge dissemination activities.

The knowledge acquired through this study on individual and societal responses to stories of human suffering will have a practical impact on future social marketing campaigns promoted by government agencies, fundraising campaigns launched by nonprofit and for-profit organizations, and the public. Results will consolidate previous knowledge while providing new insights into what prompts citizens to help others.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H4H 1R3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18-35 years of age
  • Not currently admitted to a hospital

Exclusion Criteria:

  • Not in age range (18-35 years of age)
  • Currently admitted to a hospital
  • Attended the digital storytelling workshop and made a digital story used in the RCT

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Digital storytelling group (Group 1)
Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
Other: Digital storytelling group
Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
Active Comparator: Social marketing/fundraising group (Group 2)
Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
Other: Social marketing/fundraising group
Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Empathy
Time Frame: Baseline, immediately after the intervention
Change in empathy using the Toronto Empathy Questionnaire. The minimum scoring value is 0 and the maximum scoring value is 64. A higher score means a better outcome.
Baseline, immediately after the intervention
Compassion
Time Frame: Baseline, immediately after the intervention
Change in compassion using the Compassionate Love Scale. The minimum scoring value is 1 and the maximum scoring value is 7, which comes from the average of all item scores. A higher score means a better outcome.
Baseline, immediately after the intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Positive emotions
Time Frame: Baseline, immediately after the intervention
Change in positive emotions using the Dispositional Positive Emotions Scale. The minimum scoring value is 5 and the maximum scoring value is 35. A higher score means a better outcome.
Baseline, immediately after the intervention
Mental health self-stigma
Time Frame: Baseline, immediately after the intervention
Change in mental health stigma using the Self-Stigma of Mental Illness Scale-Short Form. The minimum scoring value is 20 and the maximum scoring value is 180. A higher score means a worse outcome.
Baseline, immediately after the intervention
Mental health public stigma
Time Frame: Baseline, immediately after the intervention
Change in mental health stigma using the Difference and Disdain Scales for Public Stigma. The minimum scoring value is 9 and the maximum scoring value is 81. A higher score means a worse outcome.
Baseline, immediately after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
McGill University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Social Sciences and Humanities Research Council of Canada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 12, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 7, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 11, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 29, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 25, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 254043

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings